Ultragenyx Pharmaceutical Inc.
RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypopā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$36.26
Price+0.72%
$0.26
1Y
Price
Market Cap
$3.492b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-98.0%
EBITDA Margin-112.8%
Net Profit Margin-58.0%
Free Cash Flow MarginRevenue
$630.598m
+12.6%
1y CAGR+20.4%
3y CAGR+16.1%
5y CAGREarnings
-$579.829m
-1.9%
1y CAGR+6.2%
3y CAGR-9.3%
5y CAGREPS
-$5.94
+5.6%
1y CAGR+15.9%
3y CAGR-0.8%
5y CAGRBook Value
$16.159m
$1.190b
Assets$1.174b
Liabilities$863.113m
DebtDebt to Assets
72.5%
-1.8x
Debt to EBITDAFree Cash Flow
-$451.390m
-7.0%
1y CAGR+4.4%
3y CAGR-3.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company